Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
PRINCETON, N.J., April 17, 2024--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that new data on investigational drug UGN-102 (mitomycin) and JELMYTO and will be presented at the American Urological Association (AUA) 2024 Annual Meeting being held in San Antonio, Texas from May 3 – 6.
PRINCETON, N.J., April 15, 2024--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today announced the U.S. Food and Drug Administration (FDA) accepted the Company’s Investigational New Drug (IND) application for UGN-103, a next-generation novel mitomycin-based formulation for low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC).
Key Insights Institutions' substantial holdings in UroGen Pharma implies that they have significant influence over the...
PRINCETON, N.J., April 03, 2024--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today announced that it has filed a lawsuit in the U.S. District Court for the District of Delaware against Teva Pharmaceuticals, Inc., Teva Pharmaceuticals USA, Inc., and Teva Pharmaceutical Industries, Ltd., alleging infringement of U.S. Patent Numbers 9,040,074 ("the ’074 patent") and 9,950,069 ("the ’069
UroGen Pharma ( NASDAQ:URGN ) Full Year 2023 Results Key Financial Results Revenue: US$82.7m (up 28% from FY 2022). Net...
UroGen Pharma Ltd. (NASDAQ:URGN) Q4 2023 Earnings Call Transcript March 14, 2024 UroGen Pharma Ltd. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, ladies and gentlemen. Thank you for standing by, and welcome to the UroGen Pharma Full […]
Key Financial Metrics Indicate Progress and Hurdles for UroGen Pharma
Urogen Pharma (URGN) delivered earnings and revenue surprises of -7.46% and 5.52%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
PRINCETON, N.J., March 14, 2024--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced financial results for the fourth quarter and full year ended December 31, 2023, and provided an overview of recent developments.
PRINCETON, N.J., March 08, 2024--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the grants of inducement restricted stock units ("RSUs") to 12 new employees in connection with their employment with UroGen. These new team members will support the ongoing commercialization of Jelmyto® (mitomycin) for pyelocalyceal solution, UroGen’s first approved product, and the con